Andrea Gray
Research Subjects
Andrea Gray has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Martin L. Yarmush
Department of Biomedical Engineering, Rutgers University, Piscataway, NJ, USA
2 shared publications - Rene Schloss
Department of Biomedical Engineering, Rutgers, The State University of New Jersey, Piscataway, USA
2 shared publications - Jeffrey Barminko
Rutgers University
1 shared publication - Martin L. Yarmush
Massachusetts General Hospital, Boston, MA, USA
1 shared publication Patrick Steward
Wright State University,Electrical Engineering,Dayton,Ohio
1 shared publicationRene Schloss
Dept. of Biomedical Engineering, Rutgers, The State University of New Jersey, Piscataway, NJ, 08854
1 shared publication
Latest Publications
- 16 August 2021
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- p. 69-73
Front Collision Detection System of Unmanned Ground Vehicle using 90nm CMOS
A low power, small area front collision avoidance circuit using Light Detection and Ranging technology is presented in this paper. The proposed system would help detect and avoid the objects which would otherwise collide with an autonomous vehicle. After the front sensor detects stopped or slowed down vehicles, all sensors will turn on and make decisions based on the system's algorithm calculations. The system is implemented in CMOS 90nm technology. The power consumption of the system is 1.424mW and uses a 1.2V power supply. 4ns resolution front end sensors and 1ns resolution side sensors are used to compare the target distance with a safety standard. The processing time for making decisions is 889.5ns when the car is traveling 45mph which includes the 800ns sensor detection time.
- 16 August 2021
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- p. 69-73
Front Collision Detection System of Unmanned Ground Vehicle using 90nm CMOS
A low power, small area front collision avoidance circuit using Light Detection and Ranging technology is presented in this paper. The proposed system would help detect and avoid the objects which would otherwise collide with an autonomous vehicle. After the front sensor detects stopped or slowed down vehicles, all sensors will turn on and make decisions based on the system's algorithm calculations. The system is implemented in CMOS 90nm technology. The power consumption of the system is 1.424mW and uses a 1.2V power supply. 4ns resolution front end sensors and 1ns resolution side sensors are used to compare the target distance with a safety standard. The processing time for making decisions is 889.5ns when the car is traveling 45mph which includes the 800ns sensor detection time.
- Open Access
- 1 September 2016
- Published by World Scientific Pub Co Pte Ltd in TECHNOLOGY
- Vol. 04 (03) , 201-215
Donor variability among anti-inflammatory pre-activated mesenchymal stromal cells
Therapeutic mesenchymal stromal cells (MSCs) are attractive in part due to their immunomodulatory properties, achieved by their paracrine secretion of factors including prostaglandin E2 (PGE2). Despite promising pre-clinical data, demonstrating clinical efficacy has proven difficult. The current studies were designed to develop approaches to pre-induce desired functions from naïve MSCs and examine MSC donor variability, two factors contributing to this disconnect. MSCs from six human donors were pre-activated with interleukin 1 beta (IL-1β) at a concentration and duration identified as optimal or interferon gamma (IFN-γ) as a comparator. Their secretion of PGE2 after pre-activation and secondary exposure to pro-inflammatory molecules was measured. Modulation of tumor necrosis factor alpha (TNF-α) secretion from M1 pro-inflammatory macrophages by co-cultured pre-activated MSCs was also measured. Our results indicated that pre-activation of MSCs with IL-1β resulted in upregulated PGE2 secretion post exposure. Pre-activation with IL-1β or IFN-γ resulted in higher sensitivity to induction by secondary stimuli compared to no pre-activation. While IL-1β pre-activation led to enhanced MSC-mediated attenuation of macrophage TNF-α secretion, IFN-γ pre-activation resulted in enhanced TNF-α secretion. Donor variability was noted in PGE2 secretion and upregulation and the level of improved or impaired macrophage modulation.
- 1 September 2016
- Published by World Scientific Pub Co Pte Ltd in TECHNOLOGY
- Vol. 04 (03) , 201-215
Open AccessDonor variability among anti-inflammatory pre-activated mesenchymal stromal cells
Therapeutic mesenchymal stromal cells (MSCs) are attractive in part due to their immunomodulatory properties, achieved by their paracrine secretion of factors including prostaglandin E2 (PGE2). Despite promising pre-clinical data, demonstrating clinical efficacy has proven difficult. The current studies were designed to develop approaches to pre-induce desired functions from naïve MSCs and examine MSC donor variability, two factors contributing to this disconnect. MSCs from six human donors were pre-activated with interleukin 1 beta (IL-1β) at a concentration and duration identified as optimal or interferon gamma (IFN-γ) as a comparator. Their secretion of PGE2 after pre-activation and secondary exposure to pro-inflammatory molecules was measured. Modulation of tumor necrosis factor alpha (TNF-α) secretion from M1 pro-inflammatory macrophages by co-cultured pre-activated MSCs was also measured. Our results indicated that pre-activation of MSCs with IL-1β resulted in upregulated PGE2 secretion post exposure. Pre-activation with IL-1β or IFN-γ resulted in higher sensitivity to induction by secondary stimuli compared to no pre-activation. While IL-1β pre-activation led to enhanced MSC-mediated attenuation of macrophage TNF-α secretion, IFN-γ pre-activation resulted in enhanced TNF-α secretion. Donor variability was noted in PGE2 secretion and upregulation and the level of improved or impaired macrophage modulation.
- 11 May 2015
- Published by Wiley in Biotechnology Progress
- Vol. 31 (4) , 1058-1070
Identification of IL‐1β and LPS as optimal activators of monolayer and alginate‐encapsulated mesenchymal stromal cell immunomodulation using design of experiments and statistical methods
Induction of therapeutic mesenchymal stromal cell (MSC) function is dependent upon activating factors present in diseased or injured tissue microenvironments. These functions include modulation of macrophage phenotype via secreted molecules including prostaglandin E2 (PGE2). Many approaches aim to optimize MSC‐based therapies, including preconditioning using soluble factors and cell immobilization in biomaterials. However, optimization of MSC function is usually inefficient as only a few factors are manipulated in parallel. We utilized fractional factorial design of experiments to screen a panel of 6 molecules (lipopolysaccharide [LPS], polyinosinic‐polycytidylic acid [poly(I:C)], interleukin [IL]‐6, IL‐1β, interferon [IFN]‐β, and IFN‐γ), individually and in combinations, for the upregulation of MSC PGE2 secretion and attenuation of macrophage secretion of tumor necrosis factor (TNF)‐α, a pro‐inflammatory molecule, by activated‐MSC conditioned medium (CM). We used multivariable linear regression (MLR) and analysis of covariance to determine differences in functions of optimal factors on monolayer MSCs and alginate‐encapsulated MSCs (eMSCs). The screen revealed that LPS and IL‐1β potently activated monolayer MSCs to enhance PGE2 production and attenuate macrophage TNF‐α. Activation by LPS and IL‐1β together synergistically increased MSC PGE2, but did not synergistically reduce macrophage TNF‐α. MLR and covariate analysis revealed that macrophage TNF‐α was strongly dependent on the MSC activation factor, PGE2 level, and macrophage donor but not MSC culture format (monolayer versus encapsulated). The results demonstrate the feasibility and utility of using statistical approaches for higher throughput cell analysis. This approach can be extended to develop activation schemes to maximize MSC and MSC‐biomaterial functions prior to transplantation to improve MSC therapies. © 2015 American Institute of Chemical Engineers Biotechnol. Prog ., 31:1058–1070, 2015
- 11 May 2015
- Published by Wiley in Biotechnology Progress
- Vol. 31 (4) , 1058-1070
Identification of IL‐1β and LPS as optimal activators of monolayer and alginate‐encapsulated mesenchymal stromal cell immunomodulation using design of experiments and statistical methods
Induction of therapeutic mesenchymal stromal cell (MSC) function is dependent upon activating factors present in diseased or injured tissue microenvironments. These functions include modulation of macrophage phenotype via secreted molecules including prostaglandin E2 (PGE2). Many approaches aim to optimize MSC‐based therapies, including preconditioning using soluble factors and cell immobilization in biomaterials. However, optimization of MSC function is usually inefficient as only a few factors are manipulated in parallel. We utilized fractional factorial design of experiments to screen a panel of 6 molecules (lipopolysaccharide [LPS], polyinosinic‐polycytidylic acid [poly(I:C)], interleukin [IL]‐6, IL‐1β, interferon [IFN]‐β, and IFN‐γ), individually and in combinations, for the upregulation of MSC PGE2 secretion and attenuation of macrophage secretion of tumor necrosis factor (TNF)‐α, a pro‐inflammatory molecule, by activated‐MSC conditioned medium (CM). We used multivariable linear regression (MLR) and analysis of covariance to determine differences in functions of optimal factors on monolayer MSCs and alginate‐encapsulated MSCs (eMSCs). The screen revealed that LPS and IL‐1β potently activated monolayer MSCs to enhance PGE2 production and attenuate macrophage TNF‐α. Activation by LPS and IL‐1β together synergistically increased MSC PGE2, but did not synergistically reduce macrophage TNF‐α. MLR and covariate analysis revealed that macrophage TNF‐α was strongly dependent on the MSC activation factor, PGE2 level, and macrophage donor but not MSC culture format (monolayer versus encapsulated). The results demonstrate the feasibility and utility of using statistical approaches for higher throughput cell analysis. This approach can be extended to develop activation schemes to maximize MSC and MSC‐biomaterial functions prior to transplantation to improve MSC therapies. © 2015 American Institute of Chemical Engineers Biotechnol. Prog ., 31:1058–1070, 2015
- 27 September 2012
- Published by Springer Nature
- p. 15-38
Mesenchymal Stromal Cell Mechanisms of Immunomodulation and Homing
- 27 September 2012
- Published by Springer Nature
- p. 15-38
Mesenchymal Stromal Cell Mechanisms of Immunomodulation and Homing